These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

74 related items for PubMed ID: 19423319

  • 1. Mukitake mushroom (Panellus serotinus) alleviates nonalcoholic fatty liver disease through the suppression of monocyte chemoattractant protein 1 production in db/db mice.
    Nagao K, Inoue N, Inafuku M, Shirouchi B, Morooka T, Nomura S, Nagamori N, Yanagita T.
    J Nutr Biochem; 2010 May; 21(5):418-23. PubMed ID: 19423319
    [Abstract] [Full Text] [Related]

  • 2. Protective effects of fractional extracts from Panellus serotinus on non-alcoholic fatty liver disease in obese, diabetic db/db mice.
    Inafuku M, Nagao K, Nomura S, Shirouchi B, Inoue N, Nagamori N, Nakayama H, Toda T, Yanagita T.
    Br J Nutr; 2012 Mar; 107(5):639-46. PubMed ID: 21787451
    [Abstract] [Full Text] [Related]

  • 3. Effect of Mukitake mushroom (Panellus serotinus) on the pathogenesis of lipid abnormalities in obese, diabetic ob/ob mice.
    Inoue N, Inafuku M, Shirouchi B, Nagao K, Yanagita T.
    Lipids Health Dis; 2013 Feb 14; 12():18. PubMed ID: 23406154
    [Abstract] [Full Text] [Related]

  • 4. Effects of lotus root (the edible rhizome of Nelumbo nucifera) on the deveolopment of non-alcoholic fatty liver disease in obese diabetic db/db mice.
    Tsuruta Y, Nagao K, Shirouchi B, Nomura S, Tsuge K, Koganemaru K, Yanagita T.
    Biosci Biotechnol Biochem; 2012 Feb 14; 76(3):462-6. PubMed ID: 22451385
    [Abstract] [Full Text] [Related]

  • 5. Eicosapentaenoic acid-containing polar lipids from seaweed Susabinori (Pyropia yezoensis) alleviate hepatic steatosis in obese db/db mice.
    Yanagita T, Tsuge K, Koga M, Inoue N, Nagao K.
    Arch Biochem Biophys; 2020 Sep 30; 691():108486. PubMed ID: 32710880
    [Abstract] [Full Text] [Related]

  • 6. Dietary phosphatidylinositol prevents the development of nonalcoholic fatty liver disease in Zucker (fa/fa) rats.
    Shirouchi B, Nagao K, Inoue N, Furuya K, Koga S, Matsumoto H, Yanagita T.
    J Agric Food Chem; 2008 Apr 09; 56(7):2375-9. PubMed ID: 18324772
    [Abstract] [Full Text] [Related]

  • 7. Chromium attenuates high-fat diet-induced nonalcoholic fatty liver disease in KK/HlJ mice.
    Chen WY, Chen CJ, Liu CH, Mao FC.
    Biochem Biophys Res Commun; 2010 Jul 02; 397(3):459-64. PubMed ID: 20513351
    [Abstract] [Full Text] [Related]

  • 8. Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation.
    Larter CZ, Yeh MM, Cheng J, Williams J, Brown S, dela Pena A, Bell-Anderson KS, Farrell GC.
    J Gastroenterol Hepatol; 2008 Feb 02; 23(2):267-75. PubMed ID: 17868330
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis.
    Beraza N, Malato Y, Vander Borght S, Liedtke C, Wasmuth HE, Dreano M, de Vos R, Roskams T, Trautwein C.
    Gut; 2008 May 02; 57(5):655-63. PubMed ID: 18408102
    [Abstract] [Full Text] [Related]

  • 10. Diabetes of the liver: the link between nonalcoholic fatty liver disease and HFCS-55.
    Collison KS, Saleh SM, Bakheet RH, Al-Rabiah RK, Inglis AL, Makhoul NJ, Maqbool ZM, Zaidi MZ, Al-Johi MA, Al-Mohanna FA.
    Obesity (Silver Spring); 2009 Nov 02; 17(11):2003-13. PubMed ID: 19282820
    [Abstract] [Full Text] [Related]

  • 11. Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice.
    Wang Q, Jiang L, Wang J, Li S, Yu Y, You J, Zeng R, Gao X, Rui L, Li W, Liu Y.
    Hepatology; 2009 Apr 02; 49(4):1166-75. PubMed ID: 19177596
    [Abstract] [Full Text] [Related]

  • 12. Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease.
    Morgan K, Uyuni A, Nandgiri G, Mao L, Castaneda L, Kathirvel E, French SW, Morgan TR.
    Eur J Gastroenterol Hepatol; 2008 Sep 02; 20(9):843-54. PubMed ID: 18794597
    [Abstract] [Full Text] [Related]

  • 13. Inflammatory NF-kappaB activation promotes hepatic apolipoprotein B100 secretion: evidence for a link between hepatic inflammation and lipoprotein production.
    Tsai J, Zhang R, Qiu W, Su Q, Naples M, Adeli K.
    Am J Physiol Gastrointest Liver Physiol; 2009 Jun 02; 296(6):G1287-98. PubMed ID: 19342510
    [Abstract] [Full Text] [Related]

  • 14. Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.
    Hookman P, Barkin JS.
    Am J Gastroenterol; 2003 Sep 02; 98(9):2093-7. PubMed ID: 14499793
    [Abstract] [Full Text] [Related]

  • 15. Obesity potentiates development of fatty liver and insulin resistance, but not atherosclerosis, in high-fat diet-fed agouti LDLR-deficient mice.
    Coenen KR, Hasty AH.
    Am J Physiol Endocrinol Metab; 2007 Aug 02; 293(2):E492-9. PubMed ID: 17566116
    [Abstract] [Full Text] [Related]

  • 16. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2.
    Haukeland JW, Damås JK, Konopski Z, Løberg EM, Haaland T, Goverud I, Torjesen PA, Birkeland K, Bjøro K, Aukrust P.
    J Hepatol; 2006 Jun 02; 44(6):1167-74. PubMed ID: 16618517
    [Abstract] [Full Text] [Related]

  • 17. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
    Marsman D.
    Toxic Rep Ser; 1995 Apr 02; 30():1-G5. PubMed ID: 12209194
    [Abstract] [Full Text] [Related]

  • 18. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease.
    Targher G, Bertolini L, Rodella S, Zoppini G, Scala L, Zenari L, Falezza G.
    Clin Endocrinol (Oxf); 2006 Jun 02; 64(6):679-83. PubMed ID: 16712671
    [Abstract] [Full Text] [Related]

  • 19. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.
    Dentin R, Benhamed F, Hainault I, Fauveau V, Foufelle F, Dyck JR, Girard J, Postic C.
    Diabetes; 2006 Aug 02; 55(8):2159-70. PubMed ID: 16873678
    [Abstract] [Full Text] [Related]

  • 20. Serum ornithine carbamyltransferase reflects hepatic damage in diabetic obese mice.
    Murayama H, Ikemoto M, Hamaoki M.
    J Gastroenterol Hepatol; 2010 Feb 02; 25(2):413-9. PubMed ID: 19793175
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.